What Is Artiva Biotherapeutics, Inc. (ARTV) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Artiva Biotherapeutics, Inc.'s intrinsic value is estimated at $3.15, suggesting the stock is overvalued at its current price of $9.92. With 7 out of 9 models flagging downside (-68.3% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $9.82 (-1.0%), versus Sentiment SOTP at $0.21 (-97.8%). This +96.9% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ARTV?
9 of 13 models are currently active for ARTV. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates ARTV's intrinsic value at $2.77, implying -72.1% downside from the current price. See which stocks rank higher →
How Does ARTV Rank in Biotechnology?
Among 76 Biotechnology stocks, ARTV ranks #39 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
As a biotechnology enterprise, Artiva Biotherapeutics, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating ARTV should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ARTV a Value Trap?
CirclFi's Value Trap algorithm assigns ARTV a score of 20/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Artiva Biotherapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Artiva Biotherapeutics, Inc.'s fundamental quality profile registers 4.9/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +96.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ARTV valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ARTV's 9 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad